New immune combo aims to boost breast cancer treatment before surgery
NCT ID NCT04895761
First seen Apr 17, 2026 · Last updated May 08, 2026 · Updated 4 times
Summary
This early-phase study tests the safety of adding an immune-targeting therapy (DPX-Survivac) to standard hormone therapy (letrozole) in women with a common type of breast cancer (HR+HER2-). Some participants also receive low-dose radiation or a chemotherapy drug (cyclophosphamide). The goal is to see if these combinations are safe before surgery. Only 18 women are expected to join, and the main focus is on side effects, not yet on curing the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.